Corporate Headquarters
420 Stevens Avenue
Suite 370
Solana Beach, CA 92075

(858)345-1494 Tel.

Investor Relations :: Overview

Stock price graph

Evoke Pharma, Inc. (NASDAQ: EVOK) is a specialty pharmaceutical company focused primarily on the development of drugs to treat gastrointestinal, or GI, disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. Diabetic gastroparesis is a GI disorder afflicting millions of sufferers worldwide, in which the stomach takes too long to empty its contents resulting in serious digestive system symptoms. Metoclopramide is the only product currently approved in the United States to treat gastroparesis, and is currently available only in oral and intravenous forms. EVK-001 is a novel formulation of this drug, designed to provide systemic delivery of metoclopramide through intranasal administration.


Nov 9, 2016 at 4:30 PM ET
Evoke Pharma Third Quarter 2016 Conference Call

Sep 12, 2016 at 2:10 PM ET
Evoke Pharma to Present at Rodman & Renshaw 18th Annual Global Investment Conference

Aug 15, 2016 at 4:30 PM ET
Evoke Pharma Second Quarter 2016 Conference Call

Presentations and Posters

Evoke Pharma Investor Presentation PDF 1.0 MB  
Evoke Pharma to Present at Rodman & Renshaw 18th Annual Global Investment Conference PDF 1.1 MB  
Evoke Pharma Presentation at DDW Conference May 23, 2016 PDF 972.7 KB  

Recent Releases

Jan 9, 2017
Evoke Pharma to Attend 2017 JPMorgan Healthcare Conference

Jan 4, 2017
Evoke Provides Additional Data Demonstrating Statistically Significant Benefit for Gimoti in Moderate to Severe Patients in Phase 3 Diabetic Gastroparesis Trial

View all releases »